AW healthcare beat: $1.4bn in biotech/medtech deal making

One deal towers above the rest in our look at the $1.41 billion private capital activity in healthcare for the week of Nov. 16-20.

After operating as the venture capital arm of UK pharmaceutical giant GlaxoSmithKline (GSK) since 1985, SR One cemented its spinoff status by closing its first independent fund.

Oversubscribed at $500 million, the fund was cobbled together with support from a "pool of global institutional asset managers, endowments, foundations, pension funds and family offices," according to SR One. GSK made the largest investment in the fund, but the other players . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.

Get started

Sergio Barreto

Sergio Barreto is about 70% journalist, 30% tech geek. As an editor for The ABIS Group, he produces daily newsletters for leading healthcare and technology companies. With BMV Digital, he provides WordPress-based web developments services. Here at Alternatives Watch, he wears both hats - handling IT and occasionally writing about the intersection of alts, healthcare and tech.
Back to top button

Start Your Days in the Know

 

Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!